Nastaran Foyouzi, M.D., Marcelle I. Cedars, M.D., Heather G. Huddleston, M.D.
Vol 98, Issue 1 , Pages 151-155.e3
To compare the cost of two strategies for managing the patient with recurrent pregnancy loss (RPL).
Cost analysis using a decision analytic model was used to compare obtaining an evidence-based workup (EBW) for RPL versus obtaining a karyotype of the products of conception (POC) and proceeding with an EBW only in the setting of euploid POC.
A simulated cohort of patients experiencing a second pregnancy loss.
Main Outcome Measure(s):
Total cost of investigating the cause of RPL after a second pregnancy loss.
For all age categories, obtaining a karyotype of POC was less costly than an evidenced-based RPL evaluation. Monte Caro analysis demonstrated a net economic benefit for the karyotype strategy ($4,498 [±$792] vs. $5,022 [±$1,130]).
Our model suggests an economic advantage for obtaining a karyotype of POC in women with second miscarriage.
Read the full text at: http://www.fertstert.org/article/S0015-0282(12)00438-4/fulltext